PEN has a lower Zacks Rank (#3 Hold), significantly higher forward P/E ratio (64.35), higher PEG ratio (2.19), higher P/B ratio (8.21), and a weaker Value grade (D). These metrics indicate the stock is less attractive for value investors compared to IART.
Mixed results with strong revenue growth (14.9%) and international expansion, but offset by faster SG&A expense growth (24.1%), operating margin compression (12.0% to 10.5%), and EPS miss of 23.5%. Foreign exchange headwinds and macro sensitivity present ongoing risks despite positive product portfolio expansion.
Penumbra is the defendant in a patent-infringement lawsuit alleging unauthorized use of patented blood-clot detection technology. The lawsuit seeks damages and injunctive relief, which could impact the company's ability to sell the THUNDERBOLT system and pose financial and operational risks.
Mentioned only as the employer of Dr. Benenati; no direct business impact or strategic relationship with GuideAI is disclosed, making this a neutral mention.
Articles that tag PEN but are mainly about other companies.
Recognized as a key market player and specifically noted for launching the 3D REVASCULARIZATION catheter system in 2024, demonstrating innovation in aspiration microcatheter technology for stroke treatment.
Second-largest holding in Champlain's portfolio at $161.36 million (2.0% of AUM) and recommended by The Motley Fool.
Specialized company producing cutting-edge thrombectomy devices for stroke treatment. Acquired by Boston Scientific for $14.5 billion in January, indicating strong market value and strategic importance in addressing common medical emergencies in elderly populations.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
